Frank C. Eisenschenk

Array ( [id] => 4045390 [patent_doc_number] => 05874540 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-02-23 [patent_title] => 'CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies' [patent_app_type] => 1 [patent_app_number] => 8/318157 [patent_app_country] => US [patent_app_date] => 1994-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 13760 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/874/05874540.pdf [firstpage_image] =>[orig_patent_app_number] => 318157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3986078 [patent_doc_number] => 05959083 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-09-28 [patent_title] => 'Tetravalent bispecific receptors, the preparation and use thereof' [patent_app_type] => 1 [patent_app_number] => 8/308494 [patent_app_country] => US [patent_app_date] => 1994-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 34 [patent_no_of_words] => 5222 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/959/05959083.pdf [firstpage_image] =>[orig_patent_app_number] => 308494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3703084 [patent_doc_number] => 05646256 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-07-08 [patent_title] => 'Sata and other thiol precursors' [patent_app_type] => 1 [patent_app_number] => 8/308765 [patent_app_country] => US [patent_app_date] => 1994-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 2460 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/646/05646256.pdf [firstpage_image] =>[orig_patent_app_number] => 308765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3619665 [patent_doc_number] => 05688690 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-11-18 [patent_title] => 'Human cytotoxic lymphocyte signal transduction surface protein (P38) and monoclonal antibodies thereto' [patent_app_type] => 1 [patent_app_number] => 8/307280 [patent_app_country] => US [patent_app_date] => 1994-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 8 [patent_no_of_words] => 13059 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/688/05688690.pdf [firstpage_image] =>[orig_patent_app_number] => 307280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3445416 [patent_doc_number] => 05424066 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1995-06-13 [patent_title] => 'Method for increasing CD4+ cell numbers through the use of monoclonal antibodies directed against self-reactive, CD4 specific cytotoxic T-cells' [patent_app_type] => 1 [patent_app_number] => 8/302113 [patent_app_country] => US [patent_app_date] => 1994-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 2640 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/424/05424066.pdf [firstpage_image] =>[orig_patent_app_number] => 302113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3734355 [patent_doc_number] => 05665864 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-09-09 [patent_title] => 'Antibodies to a human integrin alpha/beta heterodimeric protein' [patent_app_type] => 1 [patent_app_number] => 8/300380 [patent_app_country] => US [patent_app_date] => 1994-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 10080 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/665/05665864.pdf [firstpage_image] =>[orig_patent_app_number] => 300380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3662566 [patent_doc_number] => 05667988 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-09-16 [patent_title] => 'Methods for producing antibody libraries using universal or randomized immunoglobulin light chains' [patent_app_type] => 1 [patent_app_number] => 8/300386 [patent_app_country] => US [patent_app_date] => 1994-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 26735 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/667/05667988.pdf [firstpage_image] =>[orig_patent_app_number] => 300386 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3994703 [patent_doc_number] => 05892019 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-04-06 [patent_title] => 'Production of a single-gene-encoded immunoglobulin' [patent_app_type] => 1 [patent_app_number] => 8/299999 [patent_app_country] => US [patent_app_date] => 1994-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 7203 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 233 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/892/05892019.pdf [firstpage_image] =>[orig_patent_app_number] => 299999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3630745 [patent_doc_number] => 05686578 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-11-11 [patent_title] => 'Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype' [patent_app_type] => 1 [patent_app_number] => 8/286430 [patent_app_country] => US [patent_app_date] => 1994-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18393 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/686/05686578.pdf [firstpage_image] =>[orig_patent_app_number] => 286430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3623147 [patent_doc_number] => 05688919 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-11-18 [patent_title] => 'Process for the purification of factor XIII, monoclonal antibodies against factor XIIIA, the preparation and use thereof' [patent_app_type] => 1 [patent_app_number] => 8/275656 [patent_app_country] => US [patent_app_date] => 1994-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2689 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/688/05688919.pdf [firstpage_image] =>[orig_patent_app_number] => 275656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3871067 [patent_doc_number] => 05837821 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-11-17 [patent_title] => 'Antibody construct' [patent_app_type] => 1 [patent_app_number] => 8/256156 [patent_app_country] => US [patent_app_date] => 1994-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 1792 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/837/05837821.pdf [firstpage_image] =>[orig_patent_app_number] => 256156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3929633 [patent_doc_number] => 05877291 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-03-02 [patent_title] => 'Multivalent single chain antibodies' [patent_app_type] => 1 [patent_app_number] => 8/263911 [patent_app_country] => US [patent_app_date] => 1994-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 24 [patent_no_of_words] => 10840 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 129 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/877/05877291.pdf [firstpage_image] =>[orig_patent_app_number] => 263911 [rel_patent_id] =>[rel_patent_doc_number] =>)